A Phase 2, Single-Arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
- Pook, David (Primary Chief Investigator (PCI))
Project: Research